Transplantation & Cellular Therapy
Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Hematopoietic cell transplantation involves replacing unhealthy bone marrow with healthy stem cells in patients with hematologic disorders. In the growing field of non-transplant cellular therapies, including chimeric antigen receptor T-cell therapies, patient- or donor-derived cells are being explored for the treatment and potential cure of blood cancers.
Advertisement
Melissa BadamoFollicular Lymphoma | February 5, 2025
The positive opinion is based on results from the phase II TRANSCEND FL study, in which liso-cel showed an ORR of 97.1%.
Read More
Andrew MorenoAcute Myeloid Leukemia | January 24, 2025
This new indication for the injection alkylating agent pertains to adult or pediatric patients aged one year and older.
Andrew MorenoTransplantation & Cellular Therapy | January 23, 2025
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Melissa BadamoTransplantation & Cellular Therapy | January 17, 2025
The CRL is related to observations of a third-party manufacturing facility as part of a standard prelicense inspection.
Andrew MorenoTransplantation & Cellular Therapy | January 17, 2025
The first-of-its-type anti-CSF-1R antibody is approved for use in adult and pediatric patients who weigh at least 40 kg.
Melissa BadamoMyeloma | January 15, 2025
Patient-reported outcomes of the CARTITUDE-4 trial showed an improvement in quality of life with cilta-cel versus SOC.
Advertisement
Melissa BadamoTransplantation & Cellular Therapy | January 16, 2025
CAR-T achieves favorable responses and survival in relapsed or refractory LBCL in both the second- and third-line setting.
Andrew MorenoMeeting News | January 16, 2025
The therapy under evaluation by two ongoing studies involves a new accelerated CAR T-cell product manufacturing process.
Nichole TuckerFollicular Lymphoma | January 10, 2025
The 5-year follow-up analysis of ZUMA-5 showed continued efficacy and no new safety signals.
Nichole TuckerMantle Cell Lymphoma | January 9, 2025
The phase 1b study of CAR22 is ongoing, and investigators are currently looking to enroll more patients.
Blood Cancers Today Staff WritersAggressive B-Cell Lymphoma | January 22, 2025
Dr. Matthew Cortese reported that CAR T-cell therapy appears to overcome some of the adverse prognostic impact.
Blood Cancers Today Staff WritersChronic Myeloid Leukemia | January 7, 2025
The study used a standard 3+3 dose escalation design to evaluate the results of SYNCAR-001 plus STK-009.
Patrick DalyFollicular Lymphoma | January 7, 2025
Data support rituximab over watchful waiting in front-line therapy for low-tumor-burden follicular lymphoma, study concludes.
Andrew MorenoTransplantation & Cellular Therapy | January 6, 2025
A compound to assist CAR T-cell therapy by targeting and suppressing YTHDF2 is in development.
Melissa BadamoTransplantation & Cellular Therapy | January 6, 2025
A new investigator-initiated trial in China will investigate KJ-C2219 for relapsed or refractory B-cell non-Hodgkin lymphoma.
Nichole TuckerTransplantation & Cellular Therapy | December 19, 2024
Approval was granted by the FDA on the basis of findings from the phase 3 MSB-GVHD001 clinical trial.
Andrew MorenoT-Cell Lymphoma | December 10, 2024
Limitations on benefits from immunotherapy in this setting increase clinical interest in this CAR T-cell therapy approach.
Andrew MorenoMeeting News | December 9, 2024
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
Andrew MorenoMeeting News | December 9, 2024
Encouraging initial study findings in mice will inform the design of a BHB supplementation trial in human patients.
Andrew MorenoMeeting News | December 9, 2024
A large, multicenter retrospective study found favorable efficacy and toxicity with this approach.
Advertisement
Advertisement